Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Standard Biotools (LAB) Change in Intangibles (2011 - 2015)

Standard Biotools (LAB) reported Change in Intangibles of $6.5 million for Q4 2015, up 12900.0% on a QoQ basis from $50000.0 in Q3 2015.

Standard Biotools (LAB) has 3 years of Change in Intangibles data on file, last reported at $6.5 million in Q4 2015.

Quarterly Change in Intangibles changed N/A year-over-year to $6.5 million in Q4 2015, while the trailing twelve-month figure through Sep 2016 was $6.5 million (up 3723.53% YoY) and the FY2017 annual result came in at $50000.0, changed N/A from the prior year.
Change in Intangibles improved to $6.5 million in Q4 2015 per LAB's latest filing, from $50000.0 in the prior quarter.
Across five years, Change in Intangibles topped out at $6.5 million in Q4 2015 and bottomed at -$2.0 million in Q4 2011.
The 3-year median for Change in Intangibles is $85000.0 (2015), against an average of $793666.7.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	-
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	-
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	-
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-31.61 Mn
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	-
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	-
10	Standard Biotools	448.37 Mn	-6.80 Mn	11.31 Mn	-

Historic Data

Download Data 🔒

Date	Value
Dec 31, 2015	6.50 Mn
Dec 31, 2015	6.50 Mn
Sep 30, 2015	50,000.00
Sep 30, 2015	50,000.00
Mar 31, 2015	120,000.00
Mar 31, 2015	120,000.00
Dec 31, 2013	197,000.00
Dec 31, 2013	197,000.00
Sep 30, 2013	-105,000.00
Sep 30, 2013	-105,000.00
Dec 31, 2011	-2.00 Mn
Dec 31, 2011	-2.00 Mn